Varian gets China OK for Halcyon system
Radiation oncology firm Varian Medical Systems has received clearance for its...Read more on AuntMinnie.comRelated Reading: Varian launches Bravos brachytherapy system Varian posts mixed results for fiscal 2018 Varian launches single-room proton therapy at ASTRO Varian acquires oncology software company Noona Varian signs educational partner in India
Despite the increasing popularity of advanced external beam radiotherapy techniques such as proton therapy and radiosurgery, radioactive plaque brachytherapy remains the dominant vision-preserving treatment for intraocular tumors [1,2]. Nowadays, the most widely used eye brachytherapy plaques are gold shells with embedded seeds of a low-energy γ emitting radionuclide such as I-125, Pd-103, and Cs-131 [1–3]. Prefabricated solid silver or platinum shells encapsulating a pure b-emitter such as Ru-106/Rh-106 and Sr-90/Y-90 are also widely used for ocular tumors
Conclusions: Our dose evaluation method can evaluate the EQD2LQLconsidering RBE changes in the dose distribution.
CONCLUSION: Dose escalation with hypofractionated proton boost was as effective as reported with high dose-rate brachytherapy boost, and the GU and GI toxicity profile was very similar. The proton boost was also appropriate for patients with larger prostate volume, higher T-stage, and high-risk disease encompassing elective regional node photon therapy. PMID: 31431382 [PubMed - as supplied by publisher]
Purpose of review To discuss alternative strategies for multimodal treatments of nonmetastatic bladder–prostate rhabdomyosarcoma performed with the aim of preserving organ function. Recent findings Bladder–prostate rhabdomyosarcomas are seldom fully resectable at presentation or after induction chemotherapy, and extensive resection might not improve survival. When an organ-sparing approach is pursued, radiotherapy might be unavoidable to achieve reliable local control of the disease. Benefits of preoperative vs. postoperative radiotherapy have yet to be investigated. Multimodal treatments may often result ...
Ocular proton therapy (OPT) is considered the elective treatment for different kinds of highly malignant intraocular tumor. Uveal, iris and conjunctival melanomas, ocular hemangioma and retinoblastomas are amongst the lesions typically treated with OPT, particularly if target thickness prevents the applicability of other treatment modalities such as brachytherapy [1 –4]. A remarkable local control rate (well over 90%) was reported over the years by several institutions with over 28.000 patients treated worldwide [1,5,6], even though concomitant counter-effects, such as radiation induced damage to the lacrimal gland, ...
The U.S. Trade Representative has approved a request from radiation oncology...Read more on AuntMinnie.comRelated Reading: Varian gets China OK for Halcyon system Varian launches Bravos brachytherapy system Varian posts mixed results for fiscal 2018 Varian launches single-room proton therapy at ASTRO Varian acquires oncology software company Noona
Radiation oncology firm Varian Medical Systems has introduced Bravos, a new...Read more on AuntMinnie.comRelated Reading: Varian posts mixed results for fiscal 2018 Varian launches single-room proton therapy at ASTRO Varian acquires oncology software company Noona Varian signs educational partner in India Varian makes changes at 2 divisions
Authors: Podder TK, Fredman ET, Ellis RJ Abstract Major categories of radiotherapy (RT) for prostate cancer (CaP) treatment are: (1) external beam RT (EBRT), and (2) brachytherapy (BT). EBRT are performed using different techniques like three-dimensional conformal RT (3D-CRT), intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT), and stereotactic body radiation therapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated proton therapy (IMPT), etc., using a variety of radiation delivery machines, such as a linear accelerator (Linac), Cyberknife robotic system, Gamma knife, Tomotherapy a...
Eye-preservation using brachytherapy (BT) and proton therapy (PT) are commonly used as primary treatments for uveal melanomas (UM). Choice of modality generally depends on local availability rather than direct assessment of the two techniques. We conducted a comparative dose planning study, estimating biologically effective doses (BED) to the tumour, macula and optic nerve head (ONH).
Age-related macular degeneration (AMD) is the leading cause of blindness in aging adults and affects millions of patients in the U.S. and even more worldwide. Existing treatments of the most devastating neovascular form of AMD involve monthly injections into the eye(s) of patients, who typically are elderly. These injections are costly and burdensome, requiring periodic intraocular injections for drug delivery. Radiation has been used to treat AMD: 6 MV external-beam radiation irradiation, proton therapy, and most recently stereotactic x-rays and beta applicators.